Novo Nordisk A/S
Pharmaceuticals
Novo Nordisk was born from a Nordic biotech lineage that begins in 1923, when Danish Nobel laureate August Krogh returned from a US lecture tour with a license to produce insulin — making Denmark one of the first countries to treat diabetes domestically. The company formed through a 1989 merger of two Danish insulin makers, Novo and Nordisk, and spent a century perfecting one product category: diabetes care.
That single-minded focus paid off spectacularly. Novo's modern pipeline produced semaglutide, marketed as Ozempic (for diabetes) and Wegovy (for obesity) — a GLP-1 drug that has become the best-selling medicine in history, with demand so explosive that Novo has outgrown its entire home country's workforce capacity. Its insulin portfolio (modern insulins and the smart pens that deliver them) still leads the world, and its obesity franchise has turned Novo into Europe's most valuable company, worth more than the entire Danish economy's GDP.
Headquartered in Bagsværd, Denmark, with about 65,000 employees and annual revenue near US$34 billion, Novo is majority-owned by the Novo Nordisk Foundation — a unique structure where the charitable foundation reinvests dividends into science. The company's challenge now is keeping up with demand: it is spending billions on new factories in Denmark, France, and the US, racing to produce enough of the weight-loss drug that reshaped global pharma.
